Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NCF1 | P14598 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6188224 | 0.80 | PDE10A (0.47) | KDM4EALDH1A1ADRB1TDP1RAB9A | |
| SCHEMBL6230177 | 0.75 | KMT2A (0.62) | KDM4EALDH1A1GAAL3MBTL1ACHE | |
| SCHEMBL2955795 | 0.74 | FUCA1 (0.60) | ALDH1A1ACHE | |
| Bromide SCHEMBL6238710 | 0.74 | KMT2A (0.61) | KDM4EALDH1A1GAAL3MBTL1ACHE | |
| SCHEMBL6373354 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1GAAL3MBTL1ACHE | |
| SCHEMBL6201186 | 0.72 | HRH3 (0.43) | KDM4EALDH1A1KMT2AHPGDRAB9A | |
| SCHEMBL6202242 | 0.71 | CHRNA7 (0.55) | KMT2ALMNA | |
| SCHEMBL20488466 | 0.71 | FUCA1 (0.60) | ALDH1A1ACHE | |
| SCHEMBL6204221 | 0.70 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPTLMNANPSR1 | |
| SCHEMBL26723750 | 0.70 | KDM4E (1.00) | KDM4EALDH1A1GAAL3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | NEUROSEARCH A/S (DK) | 2004-07-29 | — | — | US | claimed |
| EP-1397365-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NeuroSearch A/S (DK) | 2004-03-17 | — | — | EP | claimed |
| WO-2002096911-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH A/S (DK) | 2002-12-05 | — | — | WO | claimed |
| EP-1397365-B1 | HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH AS (DK) | 2005-02-16 | — | — | EP | disclosed |
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | NEUROSEARCH A/S (DK) | 2004-07-29 | — | — | US | disclosed |
| EP-1397365-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NeuroSearch A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096911-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH A/S (DK) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | CHRNA3, CHRNA5, CHRNA2 | KDM4E 2667/4885ALDH1A1 747/4885GAA 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.